Compugen has signed a collaboration agreement with Pfizer for the predictive discovery by Compugen of therapeutic peptide product candidates, for three drug targets of interest to Pfizer.
Reportedly, the discovery process, which will be based on various Compugen discovery platforms and funded by Pfizer, is expected to take a few months, following which the predicted molecules will be synthesized and delivered to Pfizer.
Following an evaluation period, Pfizer is expected to have the right to exercise options for worldwide exclusive milestone and royalty bearing licenses to develop and commercialise the selected product candidates or further optimise them to obtain final potent, selective product candidates with favorable pharmacokinetic properties.
Anat Cohen-Dayag, president and co-CEO of Compugen, said: “Although use of our various discovery platforms is now providing us with a growing inventory of drug and target candidates for further development and licensing.
“We are extremely pleased to be entering into this multi-target collaboration with Pfizer, and we look forward to entering into similar agreements with additional pharmaceutical and biopharmaceutical companies.”